Zafirlukast, like other LTRAs, performs by inhibiting the immune system. By means of its action on inflammatory cells while in the lungs, zafirlukast cuts down the creation of inflammatory mediators which are implicated while in the pathogenesis of bronchial asthma. A current study implies that T